Biologics Market By Types (Monoclonal Antibodies, Therapeutic Proteins And Vaccines), By Trends, By Regions and By Key Players - Global Forecast To 2021

Starting Price : $ 4000.00 $ 2680.00 | Pages : 220 | Published : July 2018 | SKU CODE : o&s004 | Format :

Request Sample

Biologics Market Definition

The biologics industry comprises companies manufacturing biological products. Biological products include a wide range of products such as vaccines, allergenics, somatic cells, tissues, and recombinant therapeutic proteins.  Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies. Specifically, most biologic medicines are developed using recombinant DNA (rDNA) technology.

In contrast to most chemical drugs that are chemically synthesized and their structure is known, most biologics are complex mixtures that are not easily identified or characterized. Biological products differ from conventional drugs in that they tend to be heat-sensitive and susceptible to microbial contamination. This requires sterile processes to be applied from initial manufacturing steps for Biological drugs.

Like drugs, biological products are used to either:

    • • Treat or Cure Diseases and Medical Conditions,
    • • Prevent Diseases, or
    • • Diagnose Diseases

Biologics Market Size

The global biologics market was worth $221 billion in 2017, having grown at a compound annual growth rate (CAGR) of more than 5.4% since 2013.

Growth in the biologics market in the historic period resulted from aging population, government initiatives, ability to command high prices, increased mergers and acquisitions, and increased share of biologics in the pipeline. Factors that negatively affected growth in the historic period were difficulty in manufacturing biologics, and pricing pressures from regulators. Going forward, technological advances increase in healthcare access, and reimbursement of biologics will drive growth. Factors that could hinder the growth of this market in the future include rise of biosimilars, and higher supervision during clinical.

Biologics Market Drivers

The Key drivers of the biologics market include:

Ability To Command High Prices - Biologics are used in the treatment of chronic disease conditions and unlike small molecules, the number of biosimilars (generic version of biologics) are less. This gives the monopoly to biologics and the manufacturers to state high price in the market. For instance, a biologic drug costs an average of US$ 22 per day compared to a small molecule drug that costs an average of US$1 per day. This in turn drives the biologics market.

Biologics Market Restraints

The key restraints on the biologics market include:

Difficulty In Manufacturing Biologics - Biological drugs are highly sensitive and dependent on the conditions in which they are manufactured and handled. They tend to aggregate during the production and purification process and quality control plays an important part in the manufacture of these drugs. Even minor differences in the production process can generate variations in the resulting protein, potentially leading to catastrophic results. Thus, biopharmaceutical companies manufacturing these biologicals have to put in extra care and resources, thus raising the cost and price of biologics.

Biologics Market Trends

Major trends influencing the biologics market include:

Demand For Biologics In The Treatment Of Complex Diseases - Biologics are being widely used to provide effective treatment for many complex diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease that have limited treatment options. There has been a significant advance in the treatment of rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan). Key biologics used to treat psoriasis include Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade), Secukinumab (Cosentyx). Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab), Tysabri (natalizumab) are biologics that are used to treat Crohn’s disease.

Development And Increasing Demand For Next Generation Biologics - Antibody drug conjugates (ADCs) are being used to treat diseases such as inflammatory, oncology and respiratory diseases. ADCs are monoclonal antibodies that have the ability to discriminate between healthy and diseased tissues and kill the diseased tissues when detected. ADCs are also being used in cancer treatment by attaching them to cancer-killing drugs that kill cancerous cells, leaving healthy tissues unaffected.  

Companies in the biologics market are investing in technologies to develop next generation biologics such as ADCs, bispecifics, fusion proteins, cell and gene therapy that will be more effective. These next generation biologics are expected to have better potency against the target disease as well as have the ability to treat more than one aspect of the disease. They are being manufactured with the help of technology, along with drug delivery systems. Some of the next generation biologics brands include Kadcyla, Tresiba, Alprolix, Adcetris, Eloctate, Plegridy, Afrezza. Companies such as Roche, Bristol-Myers Squibb and Novartis are investing heavily in the development of next generation biologics. The scope of market growth seems to be very high as the technology giant Samsung, through its subsidiary Samsung BioLogics Co., is investing around $740 million for the production of next-gen biologics.

Biologics Market Segmentation

The Biologics market is segmented by type, and by geography.
By Type - The biologics market can be segmented by type into
    • a) Monoclonal Antibodies (mAbs)
    • b) Therapeutic Proteins
    • c) Vaccines
Vaccines had the highest growth rate of nearly 5.86% during the historic period. The fastest growth in the historic period can be attributed to the increasing government and non-government initiatives for vaccine R&D activities and prevention of various infectious diseases. Various bivalent and pentavalent vaccines that can prevent an individual from more than one disease have also been developed and are being administered in many countries across the world.
By Geography - The biologics market is segmented into
    • o North America
      • USA
    • o Western Europe
      • UK
      • Germany
      • France
      • Spain
      • Italy
    • o Asia Pacific
      • China
      • Japan
      • India
      • Australia
    • o Eastern Europe
      • Russia
    • o South America
      • Brazil
    • o Middle East
    • o Africa
North America is the largest market for biologics, accounting for 39.5% of the global market. It was followed by Western Europe, Asia-Pacific and then the other regions. Going forward, North America and Asia-Pacific will be the fastest growing regions in this market.

Biologics Competitive Landscape

Major Competitors are:
    • • Johnson & Johnson
    • • F. Hoffmann-La Roche Ltd.
    • • Bristol-Myers Squibb Company
    • • GlaxoSmithKline Plc.
    • • AbbVie
Other Competitors Include:
    • • Amgen
    • • Sanofi S.A.
    • • Eli Lilly and Company
    • • Merck & Co.
    • • Pfizer

  1. 1.Executive Summary
  2. 2.Biologics Market Characteristics
    • 2.1.Market Overview
    • 2.2.Market Segmentation
    • 2.3.Market Value Chain
  3. 3.Biologics Market Size And Growth
    • 3.1.Biologics Historic Market Growth
      • 3.1.1.Drivers Of The Market
      • 3.1.2.Restraints On The Market
    • 3.2.Biologics Market Forecast Growth
      • 3.2.1.Drivers Of The Market
      • 3.2.2.Restraints On The Market
  4. 4.PESTLE Analysis
    • 4.1.Political
    • 4.2.Economic
    • 4.3.Social
    • 4.4.Technological
    • 4.5.Legal
    • 4.6.Environmental
  5. 5.Biologics Market Segmentation
    • 5.1.Global Biologics Market, 2017, Split By Segments, $ Billion
      • 5.1.1.Monoclonal Antibodies (mAbs)
      • 5.1.2.Therapeutic Proteins
      • 5.1.3.Vaccines
    • 5.2.Global Biologics Market, Historic and Forecast Growth Rates, Split By Segments, 2013-2021
  6. 6.Global Biologics Market Trends And Strategies
  7. 7.Global Biologics Market Compared With Similar Markets, 2017
    • 7.1.Healthcare Market Segmentation, By Region, 2017
    • 7.2.Healthcare Market Segmentation, By Country, 2017
  8. 8.Global Biologics Market Segment Details
    • 8.1.Monoclonal Antibodies (mAbs)
      • 8.1.1.Monoclonal Antibodies Market Characteristics
      • 8.1.2.Global Monoclonal Antibodies Market, 2017, By Source
      • 8.1.3.Global Monoclonal Antibodies Market, 2017, By Therapeutic Area
      • 8.1.4.Monoclonal Antibodies Market Trends And Strategies
    • 8.2.Therapeutic Proteins
      • 8.2.1.Therapeutic Proteins Market Characteristics
      • 8.2.2.Global Therapeutic Proteins Market, 2017, By Type
      • 8.2.3.Global Therapeutic Proteins Market, 2017, By Therapeutic Area
      • 8.2.4.Therapeutic Proteins Market Trends And Strategies
    • 8.3.Vaccines
      • 8.3.1.Vaccines Market Characteristics
      • 8.3.2.Global Vaccines Market, 2017, By End User
      • 8.3.3.Global Vaccines Market, 2017, By Segment
      • 8.3.4.Vaccines Market Trends And Strategies
  9. 9.Biologics Market Geography Regional and Country Analysis
    • 9.1.Biologics Market, 2017, By Region
    • 9.2.Biologics Market, Historic And Forecast Growth Rates, Split By Region, 2013-2021
    • 9.3.Biologics Market, Split By Country, 2017
    • 9.4.Biologics Market, Historic And Forecast Growth Rates, Split By Country, 2013-2021
  10. 10.Global Biologics Market Comparison With Macro Economic Factors
    • 10.1.Biologics Market Size, Percentage Of GDP, Global
    • 10.2.Per Capita Average Biologics Expenditure, Global
    • 10.3.Biologics Market Size, Percentage of GDP, By Country
    • 10.4.Per Capita Average Biologics Expenditure, By Country
  11. 11.Biologics Market Comparison With Industry Metrics
    • 11.1.Biologics & Biosimilars Sales Proportion By Country (Value), 2017, By Country
    • 11.2.Global Biologics Under Development, 2017
    • 11.3.New Biologics Approvals, 2017
    • 11.4.Number Of General Practitioners 2016, By Country
    • 11.5.Average Revenue Per General Practitioners 2016, By Country
  12. 12.Biologics Market Regional And Country Analysis
    • 12.1.Asia-Pacific Biologics Market
      • 12.1.1.Asia-Pacific Biologics Market Overview
      • 12.1.2.Asia Pacific Biologics Market
      • 12.1.3.Asia-Pacific Biologics Historic Market, 2013-2017
      • 12.1.4.Asia-Pacific Biologics Forecast Market, 2017-2021
      • 12.1.5.Asia-Pacific Biologics Market, 2017, By Segment
    • 12.2.China Biologics Market Overview
      • 12.2.1.China Biologics Market
      • 12.2.2.China Biologics Historic Market, 2013-2017
      • 12.2.3.China Biologics Forecast Market, 2017-2021
      • 12.2.4.China Biologics Market, 2017, By Segment
    • 12.3.India Biologics Market Overview
      • 12.3.1.India Biologics Market
      • 12.3.2.India Biologics Historic Market, 2013-2017
      • 12.3.3.India Biologics Forecast Market, 2017-2021
      • 12.3.4.India Biologics Market, 2017, By Segment
    • 12.4.Japan Biologics Market Overview
      • 12.4.1.Japan Biologics Market
      • 12.4.2.Japan Biologics Historic Market, 2013-2017
      • 12.4.3.Japan Biologics Forecast Market, 2017-2021
      • 12.4.4.Japan Biologics Market, 2017, By Segment
    • 12.5.Australia Biologics Market Overview
      • 12.5.1.Australia Biologics Market
      • 12.5.2.Australia Biologics Historic Market, 2013-2017
      • 12.5.3.Australia Biologics Forecast Market, 2017-2021
      • 12.5.4.Australia Biologics Market, 2017, By Segment
  13. 13.
    • 13.1.Western Europe Biologics Market
      • 13.1.1.Western Europe Biologics Market Overview
      • 13.1.2.Western Europe Biologics Market
      • 13.1.3.Western Europe Biologics Historic Market, 2013-2017
      • 13.1.4.Western Europe Biologics Forecast Market, 2017-2021
      • 13.1.5.Western Europe Biologics Market, 2017, By Segment
    • 13.2.UK Biologics Market Overview
      • 13.2.1.UK Biologics Market
      • 13.2.2.UK Biologics Historic Market, 2013-2017
      • 13.2.3.UK Biologics Forecast Market, 2017-2021
      • 13.2.4.UK Biologics Market, 2017, By Segment
    • 13.3.Germany Biologics Market Overview
      • 13.3.1.Germany Biologics Market
      • 13.3.2.Germany Biologics Historic Market, 2013-2017
      • 13.3.3.Germany Biologics Forecast Market, 2017-2021
      • 13.3.4.Germany Biologics Market, 2017, By Segment
    • 13.4.France Biologics Market Overview
      • 13.4.1.France Biologics Market
      • 13.4.2.France Biologics Historic Market, 2013-2017
      • 13.4.3.France Biologics Forecast Market, 2017-2021
      • 13.4.4.France Biologics Market, 2017, By Segment
    • 13.5.Italy Biologics Market Overview
      • 13.5.1.Italy Biologics Market
      • 13.5.2.Italy Biologics Historic Market, 2013-2017
      • 13.5.3.Italy Biologics Forecast Market, 2017-2021
      • 13.5.4.Italy Biologics Market, 2017, By Segment
    • 13.6.Spain Biologics Market Overview
      • 13.6.1.Spain Biologics Market
      • 13.6.2.Spain Biologics Historic Market, 2013-2017
      • 13.6.3.Spain Biologics Forecast Market, 2017-2021
      • 13.6.4.Spain Biologics Market, 2017, By Segment
  14. 14.
    • 14.1.Eastern Europe Biologics Market
      • 14.1.1.Eastern Europe Biologics Market Overview
      • 14.1.2.Eastern Europe Biologics Market
      • 14.1.3.Eastern Europe Biologics Historic Market, 2013-2017
      • 14.1.4.Eastern Europe Biologics Forecast Market, 2017-2021
      • 14.1.5.Eastern Europe Biologics Market, 2017, By Segment
    • 14.2.Russia Biologics Market Overview
      • 14.2.1.Russia Biologics Market
      • 14.2.2.Russia Biologics Historic Market, 2013-2017
      • 14.2.3.Russia Biologics Forecast Market, 2017-2021
      • 14.2.4.Russia Biologics Market, 2017, By Segment
  15. 15.
    • 15.1.North America Biologics Market
      • 15.1.1.North America Biologics Market Overview
      • 15.1.2.North America Biologics Market
      • 15.1.3.North America Biologics Historic Market, 2013-2017
      • 15.1.4.North America Biologics Forecast Market, 2017-2021
      • 15.1.5.North America Biologics Market, 2017, By Segment
    • 15.2.USA Biologics Market Overview
      • 15.2.1.USA Biologics Market
      • 15.2.2.USA Biologics Historic Market, 2013-2017
      • 15.2.3.USA Biologics Forecast Market, 2017-2021
      • 15.2.4.USA Biologics Market, 2017, By Segment
  16. 16.
    • 16.1.South America Biologics Market
      • 16.1.1.South America Biologics Market Overview
      • 16.1.2.South America Biologics Market
      • 16.1.3.South America Biologics Historic Market, 2013-2017
      • 16.1.4.South America Biologics Forecast Market, 2017-2021
      • 16.1.5.South America Biologics Market, 2017, By Segment
    • 16.2.Brazil Biologics Market Overview
      • 16.2.1.Brazil Biologics Market
      • 16.2.2.Brazil Biologics Historic Market, 2013-2017
      • 16.2.3.Brazil Biologics Forecast Market, 2017-2021
      • 16.2.4.Brazil Biologics Market, 2017, By Segment
  17. 17.
    • 17.1.Middle East Biologics Market
      • 17.1.1.Middle East Biologics Market Overview
      • 17.1.2.Middle East Biologics Market
      • 17.1.3.Middle East Biologics Historic Market, 2013-2017
      • 17.1.4.Middle East Biologics Forecast Market, 2017-2021
      • 17.1.5.Middle East Biologics Market, 2017, By Segment
  18. 18.
    • 18.1.Africa Biologics Market
      • 18.1.1.Africa Biologics Market Overview
      • 18.1.2.Africa Biologics Market
      • 18.1.3.Africa Biologics Historic Market, 2013-2017
      • 18.1.4.Africa Biologics Forecast Market, 2017-2021
      • 18.1.5.Africa Biologics Market, 2017, By Segment
  19. 19.Biologics Market Competitive Landscape
    • 19.1.Johnson & Johnson (J&J)
    • 19.2.F.Hoffmann-La Roche
    • 19.3.Bristol-Myers Squibb
    • 19.4.GlaxoSmithKline
    • 19.5.AbbVie
    • 19.6.Amgen
    • 19.7.Sanofi
    • 19.8.Eli Lilly and Company
    • 19.9.Merck & Co.
    • 19.10.Pfizer Inc.
  20. 20.Biologics Market Key Mergers And Acquisitions
  21. 21.Appendix
Global Biologics Market, Opportunities And Strategies Market | Characteristics, Forecast Size, Trends
Anti-Infective Drugs Market By Type of Product (antibiotics, antivirals, antifungals and others (including anthelminthic and antiprotozoal drugs)), Opportunities and Strategies – Global Forecast To 2022 
View Report
Biologics Market By Types (Monoclonal Antibodies, Therapeutic Proteins And Vaccines), By Trends, By Regions and By Key Players - Global Forecast To 2021
View Report
Pharmaceutical Drugs Market By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs) - Global Forecast To 2022
View Report
Cardiovascular Drugs Global Market Report 2019
View Report
Dermatology Drugs Global Market Report 2019
View Report
Gastrointestinal Drugs Global Market Report 2019
View Report
Hematology Drugs Global Market Report 2019
View Report
Metabolic Disorders Drugs Global Market Report 2019
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)